This seems to verify that they are going for appro
Post# of 72444

Quote:
Subsequent to the balance sheet date, the Company is establishing a wholly-owned European subsidiary for the purpose of the development of its drug candidates internationally. The subsidiary will serve as a key hub for strategic collaboration with European companies and medical communities in addition to providing cost-saving efficiencies and flexibility with respect to developing Brilacidin under European Medicines Agency standards.
As I've said before, it's possible that Bril-OM might be considered a "medical device" under European guidelines, as it is not ingested but is a "topical" treatment for the oral membranes. Medical devices are a lot easier to get approved.

